Market Minds Advisory
Cissus Quadrangularis Market

Cissus Quadrangularis Market: Cissus Quadrangularis Market. Bone and Joint Health, Sports Recovery Blends, and Indian Extraction Scale Shape Global Supply.

Cissus quadrangularis, the veldt grape, supplies standardised extracts for bone, joint, and sports recovery products, where Indian extraction scale, thin clinical evidence, adulteration control, and regulatory variation decide which suppliers hold premium contracts across supplement

Lead Analyst

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.3BMarket Size 2025
2036 FORECAST VALUE$0.7BBase Case , 2026 to 2036
CAGR 2026 TO 20368.6 %Bull 9.9% / Bear 7.3%
INCREMENTAL OPPORTUNITY$0.4BNet 10- year value creation
EXPANSION MULTIPLE2.28x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory.

Cissus quadrangularis, also called veldt grape or hadjod, is a succulent vine whose stems yield extracts standardised to ketosterones and other actives. Supplement makers sell it for bone, joint, and recovery support. Thin clinical evidence and adulteration risk shape buyer choices. Brands reward consistency over novelty.
Sports Recovery and Weight Management Cissus Blends grow fastest as sports nutrition brands add the extract to recovery and metabolic products. South Asia and Pacific holds the largest share, since Indian growers, extractors, and Ayurvedic markets control most supply and first-sale value, while North America follows through supplements and Western Europe through pharmacy channels. Assay sets price. Origin sets risk. Buyers audit suppliers yearly. Contracts run one season.
Competition is fragmented, with an Indian-American botanical actives group, an Indian natural extracts company, another Indian botanical producer, an Indian herbal extract specialist, and an Italian botanical specialist leading on stem sourcing, standardisation, and documentation, while hundreds of small Indian extractors supply lower-cost material. Supplement and traditional medicine rules govern claims. Assay gates premium accounts. Buyers test every lot. Supply contracts decide renewal. Delivery reliability decides supplier rankings. Margins follow sourcing discipline.
Market Definition
The market covers global sales of Cissus quadrangularis products, valued at supplier level, including standardised ketosterone extracts for bone and joint health, sports recovery and weight management blends, whole herb powders and crude extracts, Ayurvedic and traditional medicine grade material, and cosmetic and topical grade extracts, sold to supplement, sports nutrition, traditional medicine, and personal care makers. The scope excludes other Cissus species sold on their own, finished supplements, and synthetic bone health ingredients.
Base Year Value
$0.3B in 2025 (MMA Primary Research Dataset, September 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.6% base case. Bull 9.9%. Bear 7.3%.
Fastest Growth Segment
Sports Recovery and Weight Management Cissus Blends: 12.4% CAGR
Fastest Growth Country
India: 11.2% CAGR
Fastest Growth Region
South Asia and Pacific: 10.6% CAGR
Largest Region
South Asia and Pacific: 40% of 2025 global value
Market Leaders
Sabinsa, Arjuna Natural, Natural Remedies, Herbal Creations, Indena. Source: MMA Analysis, company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Cissus Quadrangularis Market Forecast Scenarios

cissus-quadrangularis-market-size-forecast-scenario-1789856661179
Between 2020 and 2025, Cissus quadrangularis demand grew as sports nutrition brands added it to recovery blends, bone and joint supplements broadened, and Ayurvedic and herbal markets expanded. Stem harvests and freight moved prices, evidence remained thin, and standardised extracts and blends grew faster than crude powders. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers.
The base case rests on three commercial mechanisms. First, ageing populations and active consumers keep buying bone, joint, and recovery supplements. Second, sports and weight management brands keep adopting standardised extracts in blends. Third, suppliers add assays, traceable sourcing, and clinical studies, which lift trust and widen use. Suppliers plan stem contracts, extraction, and evidence programmes around all three. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time.
The bull case needs larger clinical trials and clearer regulatory acceptance in Europe and North America, which would lift volumes. The bear case is a run of adulteration scandals combined with tighter claim rules, which would squeeze margins and slow launches. Brands reward consistency over novelty. Supply contracts decide renewal. Delivery reliability decides supplier rankings. Margins follow sourcing discipline.

Bone and Joint Demand, Sports Blends, and Indian Extraction Scale Set Cissus Outcomes

Cissus supply starts with cultivated and wild-collected stems in India, Sri Lanka, and parts of Africa, which farmers cut, slice, and dry. Extractors mill the dried stems, extract with ethanol or water, concentrate the liquid, and spray dry it into powder. They standardise the product to ketosterone or marker content and test for heavy metals, pesticide residues, and microbes before selling powders and blends to supplement makers.
MARKET CONCENTRATION24% CR5Leading five suppliers hold a low combined share
KETOSTERONE CONTENT RANGE3-6%Typical active level in standardised commercial extract grades
RAW STEM COST SHARE42%Portion of goods cost taken by dried Cissus stems
INDIA ORIGIN SHARE70%Portion of commercial stem supply grown or collected in India
SPORTS APPLICATION SHARE36%Portion of Cissus value sold into sports and weight management
BATCH CYCLE TIME6-10 daysTypical time from dried stem to finished extract lot
Marker compound content, purity, residue levels, solubility, and traceability decide value. Buyers set tight specifications, and standardised extracts with clinical summaries earn premiums of 50% to 200% over crude powders. Large botanical houses win on documentation and reach, while small Indian extractors win on cost. Suppliers with audited plants and clean traceability win, since global brands inspect closely. Audits repeat yearly. Sampling takes weeks.
Brands judge Cissus on assay, evidence, taste, and price. Sports nutrition brands want recovery claims and stable blends, bone and joint brands want clinical support, and Ayurvedic makers want authentic material. Price sensitivity is high in crude powders and moderate in standardised extracts, since dose is small but evidence is costly. Delivery slots matter as harvest is seasonal. Samples decide shortlists.
"Cissus is an old Ayurvedic herb that found a new market in gyms and joint aisles, but its evidence is still thinner than its marketing. The supplier that pairs a reliable assay with even one solid trial will beat the one that sells stem powder by the tonne."
Senior Analyst, Botanical Actives and Sports Nutrition Practice · MMA Cissus Quadrangularis Practice · September 2026

Market Trends

Sports Recovery and Weight Management Blends Add Cissus Extract

Sports nutrition and weight management brands add Cissus extract to blends with collagen, curcumin, and other actives for joint comfort and recovery, and consumers link the herb with bone and connective tissue support. Sports Recovery and Weight Management Cissus Blends grow about 12.4% a year, and blends earn gross margins of 36% to 50% against 22% to 30% for crude powders. The trend needs assay control and tolerable taste, and it rewards suppliers with blend support and documentation. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers.
Market Impact: over 200 million people have osteoporosis

Standardised Ketosterone Extracts Gain Bone and Joint Supplement Programmes

Bone and joint brands seek standardised Cissus extracts with defined ketosterone content and supporting studies, and ageing consumers look for plant-based options beside calcium and vitamin D. Standardised Ketosterone Extracts grow about 10.2% a year, and standardised grades earn gross margins of 34% to 46%. The trend needs assay methods, safety data, and small clinical studies, and it rewards suppliers that fund evidence and publish results that retailers can review. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal.
Market Impact: sports supplements grow 7-9% yearly

Market Opportunities and Growth Drivers

Ageing Populations and Bone Health Concerns Sustain Supplement Demand

Older adults worry about bone density and joint comfort, and they add supplements beside diet and prescribed care, which supports herbal options with traditional use. Over 200 million people have osteoporosis, according to global bone health estimates. The driver sustains steady demand for standardised Cissus extracts in bone and joint products and rewards suppliers with assay documentation, safety data, and consistent lots that support retailer and regulator review. Delivery reliability decides supplier rankings. Margins follow sourcing discipline. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers.
Market Impact: trials often enrol under 100 people

Sports Nutrition and Weight Management Growth Widens Herbal Blend Use

Active consumers and gym users buy recovery and metabolic blends, and brands add herbal actives with strong social media presence to differentiate their products. Sports nutrition and weight management supplements grow 7% to 9% a year in several markets. The driver sustains trial demand for Cissus blends and rewards suppliers that offer pilot batches, blend guidance, and documentation that fit tight launch calendars and cautious retailer claim rules. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal.
Market Impact: approvals can take 1-3 years

Market Restraints and Challenges

Thin Clinical Evidence Limits Premium Pricing and Claim Room

Most Cissus studies are small, short, and sometimes uncontrolled, so regulators and retailers question bone and weight claims and brands hesitate to pay high premiums. The root cause is limited funding for botanical trials. Suppliers respond with better-designed studies, though trials often enrol under 100 people and larger studies cost $0.5 million to $2 million each, which limits evidence-backed premiums to a few suppliers. Delivery reliability decides supplier rankings. Margins follow sourcing discipline. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust.
Market Impact: recovery blends grow 12.4% yearly

Adulteration and Regulatory Variation Undermine Trust and Market Access

Some Cissus products contain undeclared ingredients or low marker content, and the herb's regulatory status varies across markets, which raises risk for brands and retailers. The root cause is weak testing of raw material and inconsistent national rules. Suppliers respond with HPLC standardisation and traceability, though testing adds 3% to 6% to cost and approvals can take one to three years in cautious markets. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal. Delivery reliability decides supplier rankings. Margins follow sourcing discipline.
Market Impact: standardised extracts grow 10.2% yearly
3 additional market trends, 2 additional growth drivers, and 4 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

The global Cissus quadrangularis market is segmented by product form, which shows where standardisation, blending, and evidence create pricing power. Five segments cover standardised ketosterone extracts, sports recovery and weight management blends, whole herb powders and crude extracts, Ayurvedic and traditional medicine grade material, and cosmetic and topical grade extracts. Blends and standardised extracts grow fastest as sports
cissus-quadrangularis-market-market-share-analysis-1789856661472

Sports Recovery and Weight Management Cissus Blends

Sports Recovery and Weight Management Cissus Blends is the fastest-growing segment at 12.4% a year, about 1.44 times the overall market rate, from a moderate base. Sports nutrition and weight management brands want herbal actives in recovery blends, and gross margins of 36% to 50% against 22% to 30% for crude powders support investment. Assay control and taste are the main constraints. Suppliers with blend support and documentation win. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal. Delivery reliability decides supplier rankings.
CAGR 12.4%

Standardised Ketosterone Extracts

Standardised Ketosterone Extracts grows at 10.2% a year, because bone and joint supplement brands want defined active content and supporting studies, and buyers accept gross margins of 34% to 46% for documented, consistent lots. Thin clinical evidence and adulteration risk are the main constraints, since retailers scrutinise claims. Suppliers that fund studies, publish results, and audit raw material hold price better than followers. Margins follow sourcing discipline. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal. Delivery reliability decides supplier rankings.
CAGR 10.2%
Full segment breakdown across 5 segments available in the complete report.

Regional Architecture and Country Demand Map

South Asia and Pacific holds the largest share because India grows or collects most stems, Indian extractors make most standardised extracts, and Ayurvedic demand adds local volume, so its share sits far above the usual band. North America follows through supplements, while Western Europe and East Asia sit below

South Asia and Pacific

South Asia and Pacific holds 40% share, far above its usual band, and leads because India grows or collects about 70% of commercial Cissus stems, Indian extractors such as Sabinsa, Arjuna Natural, Natural Remedies, and Herbal Creations make most standardised extracts, and Ayurvedic markets add local demand, so first-sale value sits there. Growth exceeds the global rate. Harvest swings, adulteration scrutiny, and export documentation restrain margins. Margins follow sourcing discipline. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal. Delivery reliability decides supplier rankings.
Share: 40% | CAGR: 10.6% (2026 to 2036)

North America

North America holds 26% share, inside its band, because the United States hosts the largest sports nutrition and bone health supplement markets, and brands and contract manufacturers buy standardised extracts and blends through distributors such as Barentz and directly from Indian suppliers. Growth runs slightly below the global rate. FDA supplement rules, adulteration concerns, and claim scrutiny restrain margins, and suppliers respond with assay methods and cautious wording. Margins follow sourcing discipline. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal.
Share: 26% | CAGR: 8.4% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: Western Europe, East Asia, Middle East and Africa, Latin America, Eastern Europe. Contact sales@marketmindsadvisory.com.
cissus-quadrangularis-market-country-cagr-analysis-1789856661750

Four Margin Routes for Cissus Suppliers

Margin in Cissus comes from standardised extracts, sports blends, evidence, and secured stem supply rather than crude powder volume. The routes below apply to Indian extractors, global botanical houses, and blend suppliers, and each can start inside one planning cycle, with clear measures in gross margin points, cost per kilogram, and brand programmes served.

Moving Volume Into Standardised Ketosterone Extract Grades

Standardised grades earn gross margins of 34% to 46% against 22% to 30% for crude powders, so extractors that add HPLC methods, purification, and documentation to shift 10% of volume into standardised extracts report gross margin gains of 3 to 6 points on the mix. Upgrades cost $1 million to $4 million per site. Pilots with four brands confirm demand. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty.
Market Impact: standardised mix shift lifts gross margin by 3-6 points

Funding Larger Clinical Trials for Bone and Joint Claims

Evidence-backed extracts earn premiums of 50% to 200% over crude powders, so suppliers that fund larger, better-designed trials on bone and joint outcomes win retailer and brand programmes. Trials cost $0.5 million to $2 million each. Suppliers should publish results, share data with brands, choose narrow claims that fit European and United States rules, and reuse studies across markets. Supply contracts decide renewal. Delivery reliability decides supplier rankings. Margins follow sourcing discipline. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust.
Market Impact: evidence-backed extracts earn premiums of 50-200% over crude

Building Tested Sports Recovery Blends With Complementary Actives

Blends earn gross margins of 36% to 50%, so suppliers that combine Cissus with collagen, curcumin, and other actives and publish tolerance and stability data win sports nutrition programmes and lift sales per customer by 10% to 20%. Blend development costs $0.3 million to $1 million. Suppliers should target sports and weight management brands first and offer flavour and format support. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal. Delivery reliability decides supplier rankings. Margins follow sourcing discipline. Buyers review suppliers every season.
Market Impact: tested blends lift sales per customer by 10-20%

Contracting Traceable Stem Supply and Testing for Adulteration Control

Raw stems take about 42% of cost, and adulteration can end an account, so suppliers that contract with farmers and collectors in India and Africa, audit species, and test each lot for marker content protect premiums. Programmes cost $0.5 million to $2 million per year. Suppliers should publish certificates, cut spot purchases by 30% to 50%, and hold dried stem stock for key accounts. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty.
Market Impact: traceable contracts cut spot stem purchases by 30-50%

Who Controls the Margin Pool

The global Cissus quadrangularis market is fragmented, with a CR5 of 24%, and hundreds of small Indian extractors, regional blenders, and distributors sit outside the leading five. This assessment measures participants on estimated Cissus extract and powder sales value, held constant across all players. Sabinsa leads through stem sourcing, standardisation, and documentation, while Arjuna Natural, Natural Remedies, Herbal Creations, and Indena follow, with a clear gap between the leader and
Competition runs on four dimensions today: stem access and cost, assay standardisation, evidence and documentation, and blend support. Large houses win on evidence and reach, while small extractors win on cost and speed. Imitators copy crude extracts quickly, so premiums outside standardised and blended grades erode within a season, and price competition appears in mass supplement supply. Supply contracts decide renewal. Delivery reliability decides supplier rankings.

Emerging pressure comes from adulteration scandals, larger trials changing evidence expectations, and Chinese and Southeast Asian extractors entering with lower-cost material. Rankings shift where a supplier publishes a strong trial, wins a sports blend programme, or clears an adulteration audit. Small extractors can move up quickly, since cost and speed can outweigh legacy brands. Margins follow sourcing discipline.
cissus-quadrangularis-market-company-positioning-matrix-1789856662033

Competitive Moat and Risk Dimensions

SABINSA

Moat: Branded Actives and Documentation

Sabinsa, an Indian-American botanical actives group, sells standardised Cissus extracts under branded names and other actives to supplement brands worldwide, and controls Indian sourcing and extraction. Its brands, assay methods, and clinical work give it pricing power and credibility with global brands, and its position supports long supply relationships with sports nutrition and bone health supplement makers seeking
SABINSA

Risk: Brand Imitation and Price Pressure

Sabinsa faces imitators that copy standard extracts at lower cost, and brands may switch to cheaper generic material when clinical differentiation fades. Rivals with lower cost can win volume programmes. Buyers review suppliers every season. Batch records protect future sales. Cost control separates leaders from followers. Clear specifications build buyer trust.
ARJUNA NATURAL

Moat: Indian Sourcing and Extraction Scale

Arjuna Natural, an Indian natural extracts company, grows and sources botanicals in India and produces standardised extracts for supplement, food, and pharmaceutical customers. Its farm ties, extraction plants, and quality systems give it cost position and reliable supply, and its position supports long supply agreements with global brands and distributors who value consistent lots and competitive pricing.
ARJUNA NATURAL

Risk: Evidence and Brand Gaps

Arjuna Natural has less branded clinical evidence on Cissus than some rivals, and buyers asking for trials may prefer better-documented suppliers. Evidence gaps can limit premium pricing. Small importers feel every input swing. Technical reach compounds over time. Brands reward consistency over novelty. Supply contracts decide renewal.

Players Tracked

Prominent Players

Sabinsa
Arjuna Natural
Natural Remedies
Herbal Creations
Indena

Other Key Players

Vidya Herbs
Synthite Industries
Nutriscience Innovations
Layn Natural Ingredients
Martin Bauer Group
Euromed
Bio-gen Extracts
Konark Herbals and Healthcare
Ambe Phytoextracts
Ixoreal Biomed
Hunan NutraMax
Botanic Healthcare
Kerry Group
Givaudan
Barentz

Recent Developments

JANUARY 2026

Sabinsa Extends Standardised Cissus Range With New Assay and Safety Documentation

Sabinsa extended its standardised Cissus range with new assay and safety documentation, according to company communications. It is a product range extension, not an acquisition, and it tests whether documentation supports premium pricing. Sales volumes were not disclosed. Delivery reliability decides supplier rankings. Margins follow sourcing discipline.
Signal: Suggests leading suppliers are using assay and safety documentation to defend premiums as cheaper generic extracts spread.
FEBRUARY 2026

Arjuna Natural Announces Extraction Capacity Expansion at Indian Manufacturing Site

Arjuna Natural announced an extraction capacity expansion at an Indian manufacturing site, according to company communications. It is organic capacity expansion, not an acquisition, and it tests demand from global supplement brands. Investment values were not disclosed. Buyers review suppliers every season. Batch records protect future sales.
Signal: Confirms Indian producers are steadily adding extraction capacity to serve rising global sports and bone health supplement demand.
MARCH 2026

Indena Introduces Cissus-Based Recovery Blend With Collagen for Sports Nutrition Brands

Indena introduced a Cissus-based recovery blend with collagen for sports nutrition brands, supported by tolerance data. It is a product launch, and it tests demand for ready-made blends. Sales volumes were not disclosed. Cost control separates leaders from followers. Clear specifications build buyer trust. Technical reach compounds over time.
Signal: Indicates European botanical specialists are actively bundling Cissus into blends to win sports nutrition brands seeking documented systems.

What Drives Cissus Extract Costs

Raw Cissus stems account for roughly 42% of cost of goods, extraction and concentration about 24%, solvents and energy about 10%, and standardisation, testing, packaging, and freight about 24%. Stems come from India, Sri Lanka, and parts of Africa, and most extraction takes place in India, with smaller volumes in China and Europe and final blending near customers in North America and Europe.
The clearest recent shock came from harvest swings and energy prices. Erratic monsoons and labour shortages cut stem availability in several Indian seasons, as national agricultural reports recorded, energy prices surged in 2022, as the IEA reported, and Symrise noted in its 2024 annual report that raw material and energy costs affected its natural ingredient businesses. Suppliers raised prices by 10% to 25%. Buyers review suppliers every season.

The competitive disadvantage falls on small extractors and brands buying crude powder on spot terms, which cannot fund assays, traceability, or clinical studies. Large houses hold farmer contracts, own laboratories, and spread compliance cost across many actives. Exposure also varies by grade, since crude powder follows stem price while standardised grades depend on assay skill and evidence. Batch records protect future sales.
cissus-quadrangularis-market-cost-volatility-analysis-1789856662364

Farmer Contracts With Price Floors and Traceability

Suppliers sign multi-season contracts with farmers and cooperatives that set price floors and premiums for verified stems, and add traceability records. Contracts cut spot purchases by roughly half and reduce margin swings by 10% to 20% in volatile years. The main challenge is delivery risk, so suppliers prefinance growers and support drying and storage. Clear specifications build buyer trust.

HPLC Testing on Every Lot

Suppliers add HPLC testing on incoming stems and finished extracts, publish certificates, and audit species and residues. Testing adds 3% to 6% to cost but protects premiums and cuts rejected lots by about half. The main challenge is cost and method agreement, so suppliers share protocols with buyers and audit third-party laboratories yearly. Small importers feel every input swing.

Shared Clinical Study Programmes

Suppliers design clinical studies so data can support several brands and markets, and they share costs with partners. Data reuse cuts cost per brand by 20% to 35%. The main challenge is different claim rules, so suppliers agree data plans early, choose narrow claims, and publish results in accessible form. Technical reach compounds over time.

Portfolio Architecture for Margin Defence

Margins run from thin returns on crude powders sold in bulk to strong returns on standardised extracts and sports blends sold with documentation. Three tiers separate volume products, certified premium lines, and next-generation formats, and each tier draws on different customer groups, stem positions, and evidence platforms in a fragmented, growing market. Supply contracts decide renewal. Delivery reliability decides supplier rankings.
The tension between volume and premium is sharp. Crude powders protect plant utilisation and farmer relationships but face price swings and adulteration risk, while standardised extracts and blends earn higher margins on smaller volumes and depend on assays, evidence, and brand trust. Suppliers that run only volume struggle to fund trials, while suppliers that run only premium lack the volume to cover fixed plant cost. Margins follow sourcing discipline. Buyers review suppliers every season.

High-value pools concentrate in sports recovery blends sold to gym and weight management brands and in standardised ketosterone extracts sold to bone and joint brands. They gather where buyers pay for assay control, evidence, and documentation rather than kilograms. Ayurvedic grades add steady value in traditional medicine channels. Batch records protect future sales. Cost control separates leaders from followers.

Volume / Commodity-Adjacent Tier

Whole herb powders and crude extracts sold in bags and drums to supplement blenders and traditional medicine makers under seasonal contracts at thin margins, with price swings and adulteration risk. Clear specifications build buyer trust.
Gross Margin: 22%-30%

Premium / Certified Tier

Ayurvedic and cosmetic grade extracts with defined marker content, audit certificates, and origin documents, sold to regulated makers that require consistent lots. Small importers feel every input swing. Technical reach compounds over time.
Gross Margin: 28%-40%

Sustainability / Regulatory / Next-Generation Tier

Standardised ketosterone extracts and sports blends with assay methods, clinical summaries, and traceable sourcing, sold to brands that pay premiums for verified performance. Brands reward consistency over novelty. Supply contracts decide renewal. Delivery reliability decides supplier rankings.
Gross Margin: 34%-50%
cissus-quadrangularis-market-portfolio-architecture-1789856662664

High-value Sub-segments and Strategic Watch-out

Sports Recovery and Weight Management Cissus Blends

Sports recovery and weight management Cissus blends combine the fastest growth with strong pricing, since sports nutrition brands pay for herbal actives in recovery blends at gross margins of 36% to 50%. Assay control and tolerable taste limit competition, and suppliers with blend support win. Volume compounds as sports
Gross Margin: 36%-50%

Standardised Ketosterone Extracts

Standardised ketosterone extracts deliver strong growth and firm pricing, since bone and joint brands pay for defined active content and supporting studies. Thin evidence and adulteration risk form the entry barrier, and suppliers that fund trials and audits win. Repeat supply builds through long programmes with supplement brands and
Gross Margin: 34%-46%

Ayurvedic and Traditional Medicine Grade Material

Ayurvedic and traditional medicine grade material is the steady core, sold to herbal medicine makers at moderate margins under seasonal contracts. Value grows about 7.0% a year, and authenticity, stem access, and delivery reliability decide profit. Suppliers anchor sales on long relationships with Indian herbal companies and export distributors.
Gross Margin: 26%-38%

Whole Herb Powders and Crude Extracts

Whole herb powders and crude extracts are the strategic watch-out, since growth of about 5.4% a year trails the market, assay variation undermines trust, and buyers switch on price. Suppliers should manage this line for steady cash and redirect capacity toward higher-value standardised extracts and blends.
Gross Margin: 18%-28%

Why Supplement Brands Keep Reordering Cissus

Cissus demand behaves like an annuity attached to approved supplement formulas. Once a brand qualifies an extract whose assay, purity, and documentation it trusts, it repeats the order every quarter, and switching means new stability tests, potency checks, and possible label changes. Brands use last quarter's test results and delivery record to fix renewals, so suppliers with clean records earn steadier volume than sellers reliant on price alone.
Adoption stickiness differs by end-use vertical. Bone and joint pharmacy brands are the deepest, since extracts are written into registered formulas and change only when supply or quality fails. Sports brands follow blend performance. Weight management makers are moderate and switch on cost, while small Ayurvedic and cosmetic makers are shallow and buy through distributors. Margins follow sourcing discipline. Buyers review suppliers every season.

Buyer profiles are shifting between generations. Older brand teams bought botanicals on price and long relationships, while younger teams ask for assay data, traceable sourcing, clinical support, and clean documentation. Retailers add a third group that challenges claims. Suppliers that publish trial data and offer fast sampling win younger buyers and keep them as sports and bone health launches grow.
cissus-quadrangularis-market-end-use-penetration-index-1789856662947

MMA Verdict on Cissus Strategy

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / BLEND PORTFOLIO STRATEGY

Build Tested Sports Blends Before Recovery Brands Choose Rival Herbal Suppliers

Sports Recovery and Weight Management Cissus Blends grows at 12.4% a year, about 1.44 times the overall market rate, and suppliers that combine Cissus with collagen, curcumin, and other actives and publish tolerance and stability data earn gross margins of 36% to 50% against 22% to 30% for crude powders. Winners will invest $0.3 million to $1 million per blend and lift sales per customer by 10% to 20%. Suppliers with only crude powder will stay exposed to price competition, and rivals with proven blends will win.
02 / CLINICAL EVIDENCE STRATEGY

Fund Larger Trials Before Retailers Reject Thin Cissus Evidence and Claims

Standardised Ketosterone Extracts grows at 10.2% a year, about 1.19 times the overall market rate, but most studies enrol under 100 people, so retailers and regulators question claims. Suppliers should invest $0.5 million to $2 million per trial, publish results, share data with brands, and choose narrow claims that fit European and United States rules, earning premiums of 50% to 200% over crude powders. Those that wait for others to publish will lose position, and suppliers with owned evidence will hold pricing and retailer confidence.
03 / ADULTERATION CONTROL STRATEGY

Test Every Lot and Trace Stems Before Adulteration Scandals Damage Cissus Demand

Adulteration can end an account, testing adds only 3% to 6% to cost, and raw stems take about 42% of cost, so authenticity decides who protects premiums. Suppliers should invest $0.5 million to $2 million per year in HPLC testing, species audits, and traceable farmer contracts, cut spot purchases by 30% to 50%, and publish certificates. Those that skip testing will lose accounts after one failure, and suppliers with verified lots will hold pricing, loyalty, and shelf position across the forecast decade.
04 / REGULATORY ACCESS STRATEGY

Map Approval Paths Before Novel Ingredient Rules Restrict Cissus Abroad

Approvals can take one to three years in cautious markets, regulatory status varies widely, and North America holds 26% of the market while Western Europe holds only 12%. Suppliers should invest $0.3 million to $1 million per market in dossiers and safety data, rank markets by brand pipeline, and file where status is clearest first, reusing studies across filings. Those that assume uniform acceptance will lose launches, and suppliers with mapped approvals will hold access and pricing as the herb expands beyond India.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Cissus Quadrangularis Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Cissus Quadrangularis Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized United States sports nutrition brand with annual sales near $95 million (client-reported, unverified by MMA), selling recovery powders and joint supplements through online, gym, and specialty retail channels. It used Cissus extract in 30% of products, bought from a distributor on spot terms, and had received two retailer questions about marker content.
STRATEGIC CHALLENGE
Stem prices had risen after a poor season, one extract lot had shown low marker content, and retailers asked for assay data and narrower claims. Management needed to decide whether to contract a documented supplier, fund a trial, or reformulate, with limited capital and a retailer review date. Batch records protect future sales.
MMA APPROACH
MMA analysed sales, cost, and complaint data across 16 products, interviewed nine formulation, regulatory, and procurement experts and five suppliers, and ran a consumer survey on trust, effect, and repurchase across three states. It modelled cost by sourcing scenario, tested price spike and claim cases, and ranked options by payback and execution risk.
KEY FINDINGS
  1. A standardised extract with certificates would cost about 20% more per kilogram but meet retailer assay demands (client-reported, unverified by MMA). Cost control separates leaders from followers.
  2. A tested recovery blend could carry a documented claim and earn a price premium of about 8%. Clear specifications build buyer trust. Small importers feel every input swing.
  3. A shared clinical study with a supplier would cost about $0.5 million and support narrow claims. Technical reach compounds over time. Brands reward consistency over novelty.
  4. Two qualified suppliers would add about 4% to cost but cut supply risk by about half. Supply contracts decide renewal. Delivery reliability decides supplier rankings.
CLIENT PROFILE
The client is a mid-sized United States sports nutrition brand with annual sales near $95 million (client-reported, unverified by MMA), selling recovery powders and joint supplements through online, gym, and specialty retail channels. It used Cissus extract in 30% of products, bought from a distributor on spot terms, and had received two retailer questions about marker content.
STRATEGIC CHALLENGE
Stem prices had risen after a poor season, one extract lot had shown low marker content, and retailers asked for assay data and narrower claims. Management needed to decide whether to contract a documented supplier, fund a trial, or reformulate, with limited capital and a retailer review date. Batch records protect future sales.
MMA APPROACH
MMA analysed sales, cost, and complaint data across 16 products, interviewed nine formulation, regulatory, and procurement experts and five suppliers, and ran a consumer survey on trust, effect, and repurchase across three states. It modelled cost by sourcing scenario, tested price spike and claim cases, and ranked options by payback and execution risk.
KEY FINDINGS
  1. A standardised extract with certificates would cost about 20% more per kilogram but meet retailer assay demands (client-reported, unverified by MMA). Cost control separates leaders from followers.
  2. A tested recovery blend could carry a documented claim and earn a price premium of about 8%. Clear specifications build buyer trust. Small importers feel every input swing.
  3. A shared clinical study with a supplier would cost about $0.5 million and support narrow claims. Technical reach compounds over time. Brands reward consistency over novelty.
  4. Two qualified suppliers would add about 4% to cost but cut supply risk by about half. Supply contracts decide renewal. Delivery reliability decides supplier rankings.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1-6): Move to a standardised extract, add assay checks on each lot, and qualify a second supplier. Margins follow sourcing discipline. Phase 2: Phase 2 (Months 7-24): Run the shared study and launch a tested recovery blend with narrow claim wording. Buyers review suppliers every season. Phase 3: Phase 3 (Months 25-42): Extend standardised extracts to all products, audit suppliers yearly, and review cost and claims quarterly. Batch records protect future sales.
OUTCOME
Within 42 months, standardised extracts covered 90% of Cissus volume, assay complaints fell to zero, and gross margin on the range rose to 46% (client-reported, unverified by MMA). The client kept retailer listings, raised repurchase by 5%, and held stockouts below 3%. Cost control separates leaders from followers.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Cissus Quadrangularis Market?

The global Cissus quadrangularis market was valued at $0.28 billion in 2025 on a supplier-value basis. Growth is supported by sports and bone health demand, offset by thin evidence and adulteration risk.

How large will the Cissus Quadrangularis Market be by 2036?

The market is projected to reach $0.69 billion by 2036, up from $0.30 billion in 2026. The increase of $0.39 billion reflects sports blends, standardised extracts, and Ayurvedic demand.

What is the CAGR for the Cissus Quadrangularis Market 2026 to 2036?

The market is forecast to grow at an 8.6% CAGR from 2026 to 2036, supported by sports and bone health demand. The bull case reaches 9.9% and the bear case 7.3%, depending on evidence, testing, and regulatory access.

Which segment is growing fastest?

Sports Recovery and Weight Management Cissus Blends is the fastest-growing segment at 12.4% CAGR, roughly 1.44 times the overall market rate. Standardised Ketosterone Extracts follows at 10.2% CAGR each year.

Who are the major companies in the Cissus Quadrangularis Market?

Major companies include Sabinsa, Arjuna Natural, Natural Remedies, Herbal Creations, and Indena. Vidya Herbs, Synthite Industries, Nutriscience Innovations, Layn Natural Ingredients, and Martin Bauer Group also hold meaningful positions.

Which country is growing fastest?

India is growing fastest at about 11.2% CAGR, because extraction capacity, Ayurvedic demand, and export supplements are all expanding quickly. Sri Lanka follows as stem supply widens.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Primary Market Dimension

  • Standardised Ketosterone Extracts
  • Sports Recovery and Weight Management Cissus Blends
  • Whole Herb Powders and Crude Extracts
  • Ayurvedic and Traditional Medicine Grade Material
  • Cosmetic and Topical Grade Extracts

By End-Use Industry

  • Bone and Joint Supplements
  • Sports Nutrition
  • Weight Management Products
  • Traditional Medicine
  • Cosmetics and Personal Care

By Commercial Dimension

  • Direct Supply Contracts
  • Ingredient Distributors
  • Contract Manufacturer Programmes
  • Branded Active Licensing
  • Private Label Supply

By Region

  • South Asia and Pacific
  • North America
  • Western Europe
  • East Asia
  • Middle East and Africa
  • Latin America
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, September 2026)
Market Definition
The market covers global sales of Cissus quadrangularis products, valued at supplier level, including standardised ketosterone extracts for bone and joint health, sports recovery and weight management blends, whole herb powders and crude extracts, Ayurvedic and traditional medicine grade material, and cosmetic and topical grade extracts, sold to supplement, sports nutrition, traditional medicine, and personal care makers. The scope excludes other Cissus species sold on their own, finished supplements, and synthetic bone health ingredients.
Quantitative Units
USD billions (supplier value); metric tonnes for volume references
Segmentation Dimensions
By Product Form; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
South Asia and Pacific, North America, Western Europe, East Asia, Middle East and Africa, Latin America, Eastern Europe
Countries Covered
India, Sri Lanka, China, Japan, South Korea, Australia, United States, Canada, Germany, France, Italy, Nigeria, South Africa, United Arab Emirates, Brazil, Mexico, Poland, and additional markets relevant to this sector
Key Companies Profiled
Sabinsa, Arjuna Natural, Natural Remedies, Herbal Creations, Indena, Vidya Herbs, Synthite Industries, Nutriscience Innovations, Layn Natural Ingredients, Martin Bauer Group, Euromed, Bio-gen Extracts, Konark Herbals and Healthcare, Ambe Phytoextracts, Ixoreal Biomed, Hunan NutraMax, Botanic Healthcare, Kerry Group, Givaudan, Barentz
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-647
Published
September 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Cissus Quadrangularis Market Report (2026 to 2036).

The full report delivers a detailed assessment of the global Cissus quadrangularis market through 2036, covering product form, end-use, and regional forecasts, competitive benchmarking of leading suppliers, and input cost analysis. It combines MMA primary research, including a six-country survey of 3,800 respondents and 47 expert interviews, with public statistical and company data. Analysts also model harvest scenarios, evidence timelines, and blend adoption. Clients receive segment margin ranges, sourcing maps, and a case study on ingredient sourcing strategy. Customer programme and supply contract frameworks are also included for planning.
Ten-year form and end-use demand forecasts
Stem, solvent, and freight cost tracking
Competitive benchmarking of top twenty suppliers
Adulteration and claim rule regulatory tracker
Regional supply chain comparative analysis included
Quarterly primary survey data update access

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts